Effect of Vitamin D3 2000 IU Tablets on Serum Vitamin D 25-OH Levels, Hemoglobin Levels, Body Mass Index and CD4/CD8 Ratio in Patients Infected with Human Immunodeficiency Virus / Acquired Immunodeficiency Syndrome Who Have Been Treated with Antiretrovira

Abstract

Background: Human Immunodeficiency Virus (HIV) is a retrovirus subgroup of lentivirus family that has RNA genetic characteristics that attack the body's immune system, especially infecting Cluster Differential Four (CD4) lymphocytes and replicating according to the host's DNA. Vitamin D is important in stimulating innate immunity. Availability of vitamin D has an important role to improve the nutritional status of HIV/AIDS patients, improve the immune system, and improve prognosis. Research Objectives: To assess the effect of administration of vitamin D3 tablet therapy on serum vitamin D 25-OH levels, hemoglobin levels, body mass index (BMI), and CD4/CD8 ratio in HIV/AIDS infected patients who have been treated with antiretrovirals (ARV). Methods: This study was a cross-sectional study using 40 samples of HIV patients who were routinely controlled at the VCT polyclinic at Dr. Moewardi who received regular antiretrovirals. The inclusion and exclusion criteria are intended to obtain samples that are currently in HIV stages I and II so that it is expected to reduce other factors that cause bias levels of vitamin D apart from the chronic inflammatory process that occurs in HIV-infected patients. Patients who have come informed their consent to take blood samples during one of their visits to the VCT poly to check BMI, serum vitamin D (25-(OH)), and routine blood to determine the value of hemoglobin and the CD4/CD8 ratio. The statistical test uses an analysis of the difference in the average of the two groups. Results: The results of testing the mean difference between the two groups of serum levels of vitamin D 25-OH in the Vitamin D3 treatment and control groups showed a value of Z = -2.277 (p = 0.023). The results of the different test mean that the two groups of hemoglobin in the Vitamin D3 treatment group and the control showed a value of Z = -3.484 (p = 0.001). The results of different tests mean that the two BMI groups in the Vitamin D3 treatment group and the control group show a value of t = -5.098 (p = 0.001). The results of the mean difference test of the two CD4/CD8 ratio groups in the Vitamin D3 treatment group and the control group showed a value of t = -6.203 (p = 0.001). Conclusion: Administration of 2000 IU vitamin D3 tablets can increase serum vitamin D 25-OH levels, hemoglobin, BMI, and CD4/CD8 ratio in HIV/AIDS-infected patients treated with antiretroviral (ARV).